Inhibikase Therapeutics Ownership | Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics Ownership Summary

Inhibikase Therapeutics is owned by 4.17% institutional investors, 12.99% insiders, and 82.84% retail investors. Sands capital ventures is the largest institutional shareholder, holding 12.17% of IKT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.00% of its assets in Inhibikase Therapeutics shares.

IKT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Inhibikase Therapeutics	4.17%	12.99%	82.84%
Sector	Healthcare Stocks	42.54%	10.83%	46.63%
Industry	Biotech Stocks	45.22%	10.75%	44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Sands capital ventures	10.95M	12.17%	$17.74M
Soleus capital management	6.33M	7.03%	$10.25M
Fairmount funds management	6.13M	6.80%	$9.92M
Perceptive advisors	5.42M	6.02%	$8.78M
Commodore capital lp	5.40M	6.00%	$8.74M
Adar1 capital management	5.25M	5.83%	$8.50M
Vanguard group	3.27M	3.64%	$5.30M
Blackrock funding, inc. /de	3.08M	3.42%	$4.98M
Blackstone	2.64M	2.93%	$4.27M
Nantahala capital management	2.19M	2.43%	$3.55M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sands capital ventures	10.95M	3.89%	$17.74M
Stonepine capital management	735.02K	0.97%	$1.19M
Fairmount funds management	6.13M	0.89%	$9.92M
Adar1 capital management	5.25M	0.80%	$8.50M
Soleus capital management	6.33M	0.52%	$10.25M
Commodore capital lp	5.40M	0.43%	$8.74M
Perceptive advisors	5.42M	0.25%	$8.78M
Nantahala capital management	2.19M	0.12%	$3.55M
Caxton	16.39K	0.12%	$26.56K
Blackstone	2.64M	0.02%	$4.27M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock funding, inc. /de	3.08M	0.00%	347.02K
Adar1 capital management	5.25M	0.80%	125.50K
State street	507.75K	-	109.94K
Ubs group	136.28K	-	97.61K
Deutsche bank ag\	80.50K	-	80.50K

Top Sellers

Holder	Shares	% Assets	Change
Marshall wace, llp	-	-	-155.27K
Jane street group	-	-	-116.25K
Balyasny asset management	-	-	-81.16K
Hrt financial lp	-	-	-65.91K
Omers administration	-	-	-56.00K

New Positions

Holder	Shares	% Assets	Change	Value
Deutsche bank ag\	80.50K	-	80.50K	$130.40K
Virtu financial	13.45K	0.00%	13.45K	$22.00K
Russell investments group	7.70K	-	7.70K	$12.48K
Pnc financial services group	90.00	-	90.00	$146.00
Srs capital advisors	86.00	-	86.00	$139.00

Sold Out

Holder	Change
Raymond james financial	-1.00K
Point72 (difc)	-1.98K
Cubist systematic strategies	-9.04K
Brevan howard capital management lp	-10.38K
Capstone investment advisors	-11.07K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	12	-75.00%	3,752,410	-93.12%	4	0.11%	4	-88.57%	5	-16.67%
Jun 30, 2025	48	6.67%	54,512,380	20.28%	60	2.38%	37	19.35%	6	100.00%
Mar 31, 2025	47	51.61%	51,462,756	2.80%	57	0.13%	31	3.33%	3	-
Dec 31, 2024	31	181.82%	50,059,308	5719.28%	211	1604.08%	30	500.00%	-	-100.00%
Sep 30, 2024	11	-8.33%	860,232	2.84%	3	29.15%	5	-28.57%	2	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	2.23M	3.00%	-49.11K
iShares Russell 2000 ETF	826.22K	1.11%	-
Fidelity Small Cap Index	600.77K	0.81%	600.77K
iShares Russell 2000 Value ETF	479.39K	0.64%	-
Vanguard Institutional Extnd Mkt Idx Tr	343.15K	0.46%	-140.20K
Vanguard Russell 2000 ETF	290.81K	0.39%	-16.97K
State St Russell Sm Cap® Indx SL Cl I	211.70K	0.28%	-
Fidelity Extended Market Index	182.68K	0.25%	31.50K
Schwab Small Cap Index	152.30K	0.20%	-
NT R2000 Index Fund - NL	146.24K	0.20%	146.24K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 21, 2025	Sands Capital Life Sciences Pulse Fund II, L.P.	-	Buy	$3.00M
Oct 21, 2024	Bellini Roberto	-	Buy	$2.00M
Oct 21, 2024	Kush Arvind	-	Buy	$198.65K
Oct 21, 2024	Munshi Amit	-	Buy	$500.05K
Aug 16, 2022	Werner Milton H.	President and CEO	Buy	$4.00K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	3	-
2024 Q3	-	-
2024 Q2	-	-

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics shareholders are primarily institutional investors at 4.17%, followed by 12.99% insiders and 82.84% retail investors. The average institutional ownership in Inhibikase Therapeutics's industry, Biotech Stocks , is 45.22%, which Inhibikase Therapeutics falls below.

Who owns the most shares of Inhibikase Therapeutics?

Inhibikase Therapeutics’s largest shareholders are Sands capital ventures (10.95M shares, 12.17%), Soleus capital management (6.32M shares, 7.03%), and Fairmount funds management (6.12M shares, 6.80%). Together, they hold 26.00% of Inhibikase Therapeutics’s total shares outstanding.

Does Blackrock own Inhibikase Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Inhibikase Therapeutics.

Who is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested?

Sands capital ventures is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.89% of its assets in 10.95M Inhibikase Therapeutics shares, valued at 17.74M$.

Who is the top mutual fund holder of Inhibikase Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Inhibikase Therapeutics shares, with 3.00% of its total shares outstanding invested in 2.23M Inhibikase Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools